- Company
- The sales of flu treatment fell 99.6% due to COVID-19
- by Chon, Seung-Hyun Jan 22, 2021 06:26am
- Last year, sales of influenza drugs fell more than 60% from the previous year. The prescription of Tamiflu, the most commonly used, has dropped sharply. In the fourth quarter of last year, the season of full-fledged flu, prescriptions for Tamiflu and generics decreased by more than 99%. As the number of flu patients sharply declined due to reinf
- Company
- Pharmaceutical industry rushes to recruit new GA managers
- by Eo, Yun-Ho Jan 22, 2021 06:26am
- The pharmaceutical industry is hectic seeking for government affairs specialists to recruit. An industry source reported, many of pharmaceutical companies and Korean Research-based Pharmaceutical Industry Association (KRPIA) are in search of new government affairs or market access managers, as their previous members are transitioning to
- Company
- Viatris·Organon's prescription performance declined
- by Kim, Jin-Gu Jan 22, 2021 06:26am
- Sales of major items owned by Viatris and Organon, which were spun off from Pfizer and MSD, are declining in the domestic outpatient prescription market. As of last year, Viatris' outpatient prescriptions fell 4% and Organon's 6% YoY. The decline in prescription results for most major items, such as Viatris' Lipitor·Lyrica and Organon's Sing
- Company
- Takeda to retry expanding all-comer coverage on Zejula
- by Eo, Yun-Ho Jan 21, 2021 06:15am
- An all-comer targeting anticancer treatment Zejula is shooting yet again for the healthcare reimbursement expansion this year. The pharmaceutical industry insider reported the drug could not overcome the hurdle of the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee in last June, but the poly ADP-ribose
- Company
- Daewoong & Boryung challenged the patent for Sprycel
- by Kim, Jin-Gu Jan 21, 2021 06:13am
- Daewoong challenged the patent for BMS' chronic myelogenous leukemia treatment Sprycel (Dasatinib). As other domestic companies have failed to overcome the patents one after another, attention is focused on Daewoong's challenge. According to the pharmaceutical industry on the 19th, Daewoong recently requested an invalidation trial again
- Company
- “Yuhan’s change is just warming up with Leclaza”
- by An, Kyung-Jin Jan 21, 2021 06:13am
- “We believed the path for Yuhan Corporation taking the step forward to another century ahead would be through new drug pipeline. We are exhilarated to see the world acknowledging the company’s first proud outcome of the open innovation strategy, Leclaza (lazertinib).” During an interview with Daily Pharm on Jan. 18, Yuhan Corporation
- Company
- Tumor-agnostic Rozlytrek applies for NHI coverage
- by Eo, Yun-Ho Jan 20, 2021 06:04am
- A tumor-agnostic anticancer medicine Rozlytrek is shooting for the National Health Insurance (NHI) reimbursement listing. A pharmaceutical industry source reported Roche Korea submitted a reimbursement listing application for a neurotrophic tyrosine receptor kinase (NTRK) targeted therapy Rozlytrek (entrectinib) to a South Korean health
- Company
- Mavenclad can be prescribed at general hospitals
- by Eo, Yun-Ho Jan 19, 2021 06:02am
- New multiple sclerosis drug Mavenclad can be prescribed in general hospitals According to related industries, highly active recurrent multiple sclerosis treatment Mavenclad (Cladribine) by Merck has now passed the drug commitee (DC) of SMC, AMC, Shinchon Severance Hospital, and NCC. Mavenclad is the first short-term oral treatment that
- Company
- Big Pharmas busy reaching out for KRAS targeted therapy
- by Kim, Jin-Gu Jan 18, 2021 06:14am
- Global pharmaceutical giants are eager to develop targeted therapy for ‘Kirsten rat sarcoma viral oncogene homolog (KRAS)’ mutation, initially considered as an impenetrable technology for last four decades. Apparently, KRAS mutation is found in about one out of four cancer types. Specifically, the mutation is frequently found in canc
- Company
- Celltrion's COVID-19 antibody tx reduces progression by 54%
- by An, Kyung-Jin Jan 18, 2021 06:13am
- The result of Phase II clinical trial of Rekirona (Regdanvimab), COVID-19 antibody treatment developed by Celltrion, has been revealed for the first time. It is evaluated that it is useful to efficiently manage medical resources while reducing the incidence of severe patients requiring inpatient treatment by more than half and reducing the re
